By Josh Beckerman

 

Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S. Food and Drug Administration approved the Boston-based biotechnology company's Omisirge cell therapy for certain blood cancer patients.

Omisirge is a substantially modified allogeneic cord blood-based cell therapy aimed at quickening the recovery of neutrophils and reducing the risk of infection.

The cell therapy was approved by the FDA for patients 12 years and older with blood cancers who undergo umbilical cord blood transplantation following a myeloablative conditioning regimen.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

April 17, 2023 14:15 ET (18:15 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gamida Cell Charts.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gamida Cell Charts.